NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | Biotech Hunter

Enrollment

873

Participants

Timeline

Start Date

October 26, 2010

Primary Completion Date

January 13, 2016

Study Completion Date

April 19, 2017

Conditions

Infections, PapillomavirusPapillomavirus Vaccines

Interventions

BIOLOGICAL

GSK Biologicals' HPV vaccine 580299

Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

BIOLOGICAL

Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)

Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

Trial Locations (15)

10330

GSK Investigational Site, Bangkok

10400

GSK Investigational Site, Bangkok

10617

GSK Investigational Site, Tallinn

30322

GSK Investigational Site, Kohtla-Järve

40002

GSK Investigational Site, Khon Kaen

50200

GSK Investigational Site, Chiang Mai

400014

GSK Investigational Site, Mumbai

411001

GSK Investigational Site, Pune

600113

GSK Investigational Site, Chennai

700026

GSK Investigational Site, Kolkata

90035003

GSK Investigational Site, Porto Alegre

14049-900

GSK Investigational Site, Ribeirão Preto

13083-970

GSK Investigational Site, Campinas

21040-360

GSK Investigational Site, Rio de Janeiro

03015000

GSK Investigational Site, São Paulo